| Record ID | marc_columbia/Columbia-extract-20221130-030.mrc:72368102:3569 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-030.mrc:72368102:3569?format=raw |
LEADER: 03569cam a2200577Mi 4500
001 14696406
005 20200430222900.0
006 m o d
007 cr |||||||||||
008 150115t20152015fluad ob 001 0 eng d
035 $a(OCoLC)897882955
035 $a(OCoLC)ocn897882955
035 $a(NNC)14696406
040 $aUAB$beng$erda$epn$cUAB$dOCLCO$dCRCPR$dYDXCP$dE7B$dOCLCF$dEBLCP$dHV6$dTPH$dOCLCA$dYDX$dOCLCA$dOCLCQ$dMERUC$dOCLCO$dOCLCQ$dWYU$dOCLCA$dTYFRS$dOCLCQ$dUKAHL
019 $a899156908$a966180646$a966462942$a1066619172
020 $a9781482216752$q(e-book ;$qPDF)
020 $a1482216752$q(e-book ;$qPDF)
020 $z9781482216745
020 $z1482216744
050 4 $aRM301.25$b.S73 2015
060 4 $aQV 785
082 04 $a615.19$bS797
049 $aZCUA
245 00 $aStatistical methods in drug combination studies /$cedited by Wei Zhao, MedImmune, LLC, Gaithersburg, Maryland, USA ; Harry Yang, MedImmune, LLC, Gaithersburg, Maryland, USA.
264 1 $aBoca Raton :$bCRC Press,$c[2015]
264 4 $c©2015
300 $a1 online resource.
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aChapman & Hall/CRC biostatistics series
504 $aIncludes bibliographical references and index.
505 0 $aDrug combination : much promise and many hurdles / Harry Yang and Laura Richman -- Drug combination synergy / Harry Yang, Steven J. Novick, and Wei Zhao -- Drug combination design strategies / Steven J. Novick and John J. Peterson -- Confidence interval for interaction index / Maiying Kong and J. Jack Lee -- Two-stage response surface approaches to modeling drug interaction / Wei Zhao and Harry Yang -- A Bayesian industry approach to phase I combination trials in oncology / Beat Neuenschwander [and five others] -- Statistical methodology for evaluation combination therapy in clinical trials / H.M. James Hung, Sue-Jane Wang -- Challenges and opportunities in analysis of drug combination clinical trial data / Yaning Wang, Hao Zhu, Liang Zhao, and Ping Ji -- Statistical computational tools for ADA analysis / Cheng Su.
520 $aDrug combination research has become increasingly important as multi-drug treatments may overcome disease resistance to monotherapies given the heterogeneous nature of complex diseases, such as cancer. To screen for potential candidates, rigorous statistical methods must used to avoid a high proportion of false-positive recommendations, resulting in a tremendous waste of time and resources. This book covers all statistical aspects of drug combination research, from designing in vitro drug combination studies to analyzing clinical trial data.
650 0 $aDrug development.
650 0 $aDrugs$xResearch.
650 12 $aDrug Combinations.
650 22 $aClinical Trials as Topic.
650 22 $aModels, Statistical.
650 22 $aDrug Design.
650 22 $aDrug Therapy, Combination.
650 7 $aDrug development.$2fast$0(OCoLC)fst00898670
650 7 $aDrugs$xResearch.$2fast$0(OCoLC)fst00898894
655 4 $aElectronic books.
655 0 $aElectronic book.
700 1 $aZhao, Wei,$d1975-$eeditor.
700 1 $aYang, Harry,$eeditor.
776 08 $iPrint version:$aZhao, Wei.$tStatistical Methods in Drug Combination Studies.$dHoboken : Taylor and Francis, ©2015$z9781482216745
830 0 $aChapman & Hall/CRC biostatistics series.
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio14696406$zTaylor & Francis eBooks
852 8 $blweb$hEBOOKS